JNJ vs MRNA
By Alex · Tickerpine
Johnson & Johnson vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | MRNA |
|---|---|---|
| Price | $260.86 | $63.67 |
| Market cap | $628.65B | $25.42B |
| P/E ratio | 30.3 | — |
| ROE | 25.74% | -39.00% |
| Profit margin | 21.48% | -141.43% |
| Revenue growth | 6.60% | 2.10% |
| Dividend yield | 2.05% | — |
| Beta | 0.23 | 0.90 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs MRNA in plain English
- JNJ is the bigger company — about 24.7× the market cap of MRNA.
- JNJ earns a higher return on equity (26% vs -39%).
- JNJ is growing revenue faster (7% vs 2%).
- JNJ pays a dividend (2.05%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.